Vimarsana
Biggest News Aggregation in the World

Diagnostic Modalities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diagnostic Modalities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diagnostic Modalities Today - Breaking & Trending Today

"Sonographic Assessment of Hand Injuries: Diagnostic Accuracy and Revie" by O. Kenechi Nwawka, Ravi Desai et al. - Vimarsana News

"Sonographic Assessment of Hand Injuries: Diagnostic Accuracy and Revie" by O. Kenechi Nwawka, Ravi Desai et al.

Background: The high soft-tissue contrast of magnetic resonance imaging (MRI) makes it useful for evaluation of hand injuries, but its limitations include cost, imaging artifacts, and patient claustrophobia. Ultrasound is readily available, fast, noninvasive, and radiation free, but its utility for the evaluation of hand soft-tissue injury and pathology is less well known. Purpose: We sought to examine the accuracy of ultrasound for the evaluation of hand injury at a single institution. Methods: We queried a radiology information system for ultrasound cases between 2014 and 2020 at a tertiary ...

Source: uow.edu.au
Centessa Pharmaceuticals plc: Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting - Vimarsana News

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting

New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentationBOSTON and LONDON, Nov. 03, 2022 (GLOBE

Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting - Vimarsana News

Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting

03.11.2022 - New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentationBOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) - Centessa Pharmaceuticals plc ... Seite 1

Biomed Israel Marks 20th Anniversary - Vimarsana News

Biomed Israel Marks 20th Anniversary

/PRNewswire/ -- Biomed Israel, the premier international Life Science and HealthTech conference in Israel, marks its 20th anniversary on May 10-12, 2022, at...

Biomed Israel Marks 20th Anniversary - Vimarsana News

Biomed Israel Marks 20th Anniversary

/PRNewswire/ -- Biomed Israel, the premier international Life Science and HealthTech conference in Israel, marks its 20th anniversary on May 10-12, 2022, at...